Procalcitonin in Hepatocellular Carcinoma

Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01518829

Enrollment

Registered

2012-01-26

Start date

2012-04-30

Completion date

2013-01-31

Last updated

2013-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

hepatocellular carcinom, postablation syndrom, procalcitonin

Brief summary

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. \- Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency. 2. \- Fever more than 38C after 48 hours post intervention.

Exclusion criteria

1. HCC Patients who does not develop fever after intervention. 2. Proven infection elsewhere (e.g. UTI, chest infection..)

Design outcomes

Primary

Measure	Time frame
Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma	6months

Countries

Egypt

Outcome results